Skip to main content

Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients

Buy Article:

$51.00 plus tax (Refund Policy)


Raso T, Bianco O, Grosso B, Zucca M, Savoia D. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients. Brief report. APMIS 2008;116:837–41.

Achromobacter xylosoxidans is a ubiquitous Gram-negative non-fermenting rod, recently characterized as an emerging pathogen in cystic fibrosis (CF) patients. Its pathogenic potential and prevalent transmission routes are still unclear. This study investigated the PFGE genetic pattern and antimicrobial resistance profile of 42 A. xylosoxidans isolates obtained over 4 years from the respiratory tract of 22 CF patients. By genotypic analysis, 31 isolates were attributed to 8 distinct PFGE patterns (A–H), whereas 11 isolates were not typable because their DNA was not restricted by XbaI and DraI restriction enzymes. The majority of the isolates showed multidrug resistance; imipenem and piperacillin were the most active drugs. During the course of A. xylosoxidans chronic infection forced expiratory volume and body mass index values were not significantly lowered. The demonstration of widespread antibiotic resistance underscores the importance of antibiogram-directed therapy. Our data suggest that in some cases the infection may have been acquired from other patients or from a common contaminated source. Further epidemiological studies may be important for the design and implementation of prophylactic measures in CF centers.

Keywords: Achromobacter xylosoxidans; antibiotic resistance; cystic fibrosis; genotype; respiratory tract infections

Document Type: Research Article


Affiliations: 1: Department of Clinical and Biological Sciences, University of Torino 2: Laboratory 3: Respiratory Disease Division, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy

Publication date: September 1, 2008

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more